$UTMD

Utah Medical sets 31-cent payment for shareholders on Oct. 5

Utah Medical Products (Nasdaq: UTMD) said its board approved a quarterly cash dividend of $0.31 per share payable Oct. 5, 2026 to shareholders of record as of Sept. 17, 2026. The company stated this is a 1.6% increase versus the dividend declared for the same quarter a year earlier.

Original reporting
Published Aug 4, 2026, 2:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 4, 2026, 5:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$UTMD
Bullish
medium confidence
Mentioned
$UTMD
Relevance
5/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$UTMDBullishLow
01

Why it matters

For UTMD, the key tradable elements are the dividend amount ($0.31), the record date (Sept. 17, 2026), and the payment date (Oct. 5, 2026). The disclosure does not include earnings, guidance, or other fundamental changes.

02

Market read

This is a routine dividend declaration with a modest YoY increase, offering limited incremental information for price discovery.

03

What to watch

Traders may focus more on ex-dividend date mechanics and yield relative to peers than on the declaration itself, since no operational catalyst is provided.

Relevance 5/10Novelty 5/10Timing: dividend payable Oct. 5, 2026, with record date Sept. 17, 2026

Background

The company announced a quarterly cash dividend approved by its board, including the record date and payment date.

Company-level read

Ticker impact

$UTMDBullishMedium confidence
Context

Utah Medical Products’ board approved a $0.31 quarterly cash dividend payable Oct. 5, 2026, with a Sept. 17 record date.

Expected impact

Low near-term impact; any reaction is likely limited to dividend-focused flows around the declaration and ex-dividend timing.

Evidence & confidence

The article discloses a routine quarterly dividend and a small 1.6% YoY increase, with no guidance, earnings, or balance-sheet change.

Market effects

Limited read-through to medical device peers; dividend announcements are typically company-specific.

Minimal, as this is a single-company corporate action.

Low, no cross-border deal, regulation, or supply-chain event mentioned.

Counterpoint

The dividend increase is small (1.6% YoY), so it may not offset any underlying concerns about growth or margins.

Key entities

  • Utah Medical Products, Inc.

    Nasdaq-listed medical device company that approved a quarterly cash dividend of $0.31 per share.

  • Board of Directors

    Approved the quarterly cash dividend and set the record and payment dates.

Related articles

$UTMDMed

UTAH MEDICAL PRODUCTS INC (UTMD): Results of Operations and Financial Condition

UTAH MEDICAL PRODUCTS INC (UTMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 utmd_ex99z1.htm EXHIBIT 99.1 EXHIBIT 99.1 UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2026 Contact: Brian Koopman (801) 566-1200 July 23, 2026 Salt Lake City, Utah – Utah Medical Products, Inc. [Nasdaq: UTMD] reports second calendar qua

$SABRMedAI 8/10

Sabre (SABR) Prices $1.35B of Secured Notes. Is the Breathing Room Worth the Cost?

Sabre Corporation (SABR) priced a $1.35 billion offering of 9.875% senior secured notes, up from $1.1 billion. Proceeds will refinance existing debt, including $1 billion of 11.125% notes due in 2029. The move aims to extend maturities and reduce coupon rates, but costs and cash generation remain concerns. Q2 revenue and operating income rose 4% each, but free cash flow was negative in the first half.

$ZCSHHigh

Zcash ETF Activity Surges as Grayscale Plans 3-for-1 Share Split

Grayscale's Zcash ETF (ZCSH) will undergo a 3-for-1 share split on September 29, with adjusted shares trading from September 30. The fund's assets have grown to $890M, with net inflows exceeding $233M since its August launch. Zcash (ZEC) has seen increased institutional interest and a new all-time high price of $1,521, alongside an upcoming network upgrade (NU7).